<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>APPROVED</status><version>v2</version><patient-age>83</patient-age><report-id>PHHY2012BR113348</report-id><gender>female</gender><reactions><reaction>Mental problems</reaction><reaction>Asthmatic problems/ episode of asthma</reaction><reaction>Lack of memory</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>FORASEQ</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Dyspnoea</indication></indications><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Brazil</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053137_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133934</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012BR113348</safetyreportid>
		<primarysourcecountry>BR</primarysourcecountry>
		<occurcountry>BR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-05</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-05</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012BR113348</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>BR</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>EAS</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19290205</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Asthma</patientepisodename>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Mental problems</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Mental disorder</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Mental disorder</reactionmeddrapt>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Asthmatic problems/ episode of asthma</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Asthma</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Asthma</reactionmeddrapt>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Lack of memory</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Loss of memory</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Amnesia</reactionmeddrapt>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>FORASEQ</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationnumb>20-831</drugauthorizationnumb>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>UNK UKN, BID</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Dyspnoea</drugindication>
				<actiondrug code="1">Drug Withdrawn</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>FORMOTEROL FUMARATE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>BUDESONIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Amnesia</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Amnesia</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Asthma</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Asthma</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mental disorder</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Mental disorder</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012BR113348 is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report from a consumer via Vale Mais Saude Marketing Program received on 05 Dec 2012. This is also a quality complaint (AQWA pending). This report refers to an <Semaphore x="1387834" class="Patient Age" value="83" score="1.00" ID=""><Semaphore x="5960701642276865" class="Patient Age" value="83" score="1.00" ID="">83 </Semaphore>year old </Semaphore>female patient. The patient's medical history included <Semaphore x="1550634" class="Disease or Finding" value="Asthma" score="1.00" ID="C28397">asthma</Semaphore>. The patient received Foraseq (<Semaphore x="601266" class="Medicine" value="formoterol" score="0.49" ID="251425">formoterol </Semaphore>fumarate/budesonide) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore><Semaphore x="1870759" class="Disease or Finding" value="Dyspnea" score="1.00" ID="C2998">of <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968">shortness of breath </Semaphore></Semaphore>from 5 years ago at an unspecified dose, BID. One year ago, on an unspecified date, the patient was 10 days at the <Semaphore x="3043968" class="MedDRA LLT" value="Intensive care" score="1.00" ID="10022519">intensive care </Semaphore>unit due to <Semaphore x="2765453" class="MedDRA LLT" value="Asthma" score="1.00" ID="10003553">asthmatic </Semaphore>and mental problems. Foraseq was discontinued on an unspecified date. Six months ago after stopping Foraseq, the patient experienced an episode of <Semaphore x="1550634" class="Disease or Finding" value="Asthma" score="1.00" ID="C28397">asthma </Semaphore>again. Three months ago, she presented lack of memory. It was treated with <Semaphore x="560518" class="Medicine" value="Exelon" score="0.49" ID="249270">Exelon </Semaphore>transdermal at the dose of 4.6 mg/5cm2, daily. The patient would return using Foraseq 12/400 ug. Causality and seriousness were not provided. The event <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was reported as condition improving.</narrativeincludeclinical>
				<sendercomment>Mac: Event Asthma episode is possibly due to natural coarse of disease. Causal relationship of events asthma and mental problems with Foraseq is not assessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>